Laminopathy
MONDO:0021106A rare genetic disorder caused by mutations in genes encoding proteins of the nuclear lamina.
19 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for rare fat disorder: daily leptin shots target blood sugar and fats
Disease control OngoingThis Phase 3 trial tests whether a daily injection of metreleptin (a lab-made leptin hormone) can improve blood sugar and fat levels in people with partial lipodystrophy, a rare condition where fat is distributed abnormally. About 69 participants will receive either metreleptin o…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare fat disorder: experimental drug mibavademab under safety review
Disease control OngoingThis study tests the safety of switching from the current drug metreleptin to a new experimental drug called mibavademab in people with generalized lipodystrophy, a rare condition where the body cannot properly store fat. Nine participants who have been stable on metreleptin will…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to slow Progeria's effects
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding everolimus to the existing drug lonafarnib can better control progeria, a rare disease that causes rapid aging in children. About 80 children with confirmed progeria will take both pills by mouth. The first part finds the safest dose of everolimus,…
Phase: PHASE1, PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for kids with rapid-aging disease: drug combo tested
Disease control OngoingThis study tests a new drug called progerinin, given together with the standard medicine lonafarnib, in 10 children with Hutchinson-Gilford progeria syndrome (a rare disease that causes rapid aging). The goal is to find the best dose and check if the combination is safe and toler…
Phase: PHASE2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC